26 Drugmakers Sign Pricing Agreements With the Trump Administration

The federal government has reached pricing agreements with 26 pharmaceutical companies under a Most Favored Nation (MFN) framework, according to Healthcare Dive, reported September 21, 2026. MFN pricing is a policy approach that ties U.S. drug prices to the lowest price a manufacturer charges in other wealthy countries. Healthcare Dive reports that while the deals are framed as a win for lowering what Americans pay for prescription drugs, they could also complicate other federal and state efforts already underway to reduce the country's overall drug spend.

For readers on Medicare, or helping a parent navigate Part D coverage, this matters because drug pricing policy shifts at the federal level tend to filter down into plan formularies, negotiated prices, and premium calculations over time. It's worth understanding what's known, what's still unclear, and what to watch for as these agreements take effect.

What the MFN Deals Are Reported to Do

Under the Most Favored Nation model, the administration has pursued agreements directly with drug manufacturers rather than relying solely on the drug price negotiation program created by the Inflation Reduction Act of 2022, which currently applies to a limited set of high-spend Medicare drugs. Healthcare Dive's reporting describes the 26 company agreements as a parallel track: pricing commitments negotiated company by company, rather than a single across-the-board rule.

The publication's core finding is that this approach creates what it calls a hidden tradeoff. Because the MFN agreements operate outside the existing Medicare drug negotiation structure, they could interact with, duplicate, or in some cases undercut savings that the IRA's negotiation program and state-level purchasing efforts are designed to produce. Healthcare Dive does not characterize this as a legal violation or as bad faith on the part of any company or agency, it frames it as a structural tension between two different cost-control mechanisms operating at the same time.

Why This Creates Uncertainty for Medicare Enrollees

Medicare's Part D program covers outpatient prescription drugs and negotiates directly with manufacturers on a defined list of drugs each year under the IRA program. When a second, separate pricing framework is layered on top of that, as Healthcare Dive describes with the MFN deals, it becomes harder to predict which price a given plan will actually see, and how quickly that price change reaches an enrollee's copay or coinsurance.

The practical uncertainty for readers falls into three buckets: whether MFN pricing lowers list prices that Part D plans use to set formularies, whether it changes the size of savings already expected from the IRA negotiation program for 2026 and 2027 drug cohorts, and whether any near-term price changes reach patients faster than the multi-year phase-in schedule the IRA negotiations already follow. None of these questions have clear answers yet based on the reporting, and Healthcare Dive itself frames the interaction as a risk to monitor rather than a settled outcome.

Key Takeaway

A Most Favored Nation pricing agreement is not the same as a Medicare price change. Even if a manufacturer signs an MFN deal, your Part D plan's formulary price, copay, and coverage rules for 2026 and 2027 are set separately, through CMS's own negotiation calendar and each plan's annual bid process. Don't assume a headline drug deal changes your out-of-pocket cost until it shows up in your plan's formulary or Explanation of Benefits.

What Medicare Beneficiaries and Families Should Do Now

Because these are federal policy negotiations still working through implementation, there's no action to take today that would change your current drug costs. But there are a few things worth tracking heading into Medicare's Annual Enrollment Period, which runs October 15 through December 7 each year, and into 2027 plan year decisions:

Check your plan's formulary each fall. Whatever happens with MFN agreements at the manufacturer level, the number that matters to you is the tier and copay listed on your specific Part D or Medicare Advantage plan's drug formulary. Formularies can change year to year even when a drug's negotiated price does not move.

Watch for updates on the IRA negotiation program. The Inflation Reduction Act's Medicare Drug Price Negotiation Program already has a public schedule of which drugs are subject to negotiated pricing and when those prices take effect. If MFN agreements end up duplicating or offsetting those savings, as Healthcare Dive's reporting suggests is possible, that's the program most likely to show a visible effect on your plan's pricing first.

Ask a licensed agent or SHIP counselor before switching plans based on drug pricing news. Headlines about federal drug deals move fast, but plan-level pricing changes move on Medicare's own calendar. A State Health Insurance Assistance Program (SHIP) counselor or a licensed Medicare agent can confirm what a specific drug actually costs under a specific plan before you make a coverage change during Annual Enrollment.

Keep an eye on your specific medications. If you or a family member take a high-cost brand-name drug, that's the category most likely to be affected by either the MFN agreements or the IRA negotiation program. Generic and widely available medications are less likely to see near-term pricing shifts from either mechanism.

The bottom line for now: the 26 pharmaceutical pricing agreements reported by Healthcare Dive represent a significant policy development, but the practical effect on what Medicare enrollees pay at the pharmacy counter in 2026 and 2027 remains unclear. Readers should treat this as a story to watch rather than a reason to make coverage decisions today, and should confirm any specific drug cost question with their plan or a licensed agent before Annual Enrollment closes on December 7.